Cash and Cash Equivalents Rise to $217 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
Should l Buy IMRX?
Cash, cash equivalents and marketable securities as of December 31, 2025 were $217.0 million, compared with $36.1 million as of December 31, 2024.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMRX
Wall Street analysts forecast IMRX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.330
Low
11.00
Averages
14.50
High
20.00
Current: 5.330
Low
11.00
Averages
14.50
High
20.00
About IMRX
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immuneering Reports Q4 EPS Beat with Strong Cash Position
- Earnings Highlights: Immuneering reported a Q4 GAAP EPS of -$0.18, beating expectations by $0.13, indicating resilience in financial performance despite a challenging market environment.
- Strong Cash Reserves: As of 2025, Immuneering holds $217 million in cash, cash equivalents, and marketable securities, with an anticipated runway extending into 2029, ensuring operational stability for the coming years.
- Clinical Trial Progress: The company reported a positive 12-month overall survival update from the Phase IIa trial of Atebimetinib for pancreatic cancer, demonstrating potential therapeutic value despite a stock price decline due to data volatility.
- Nasdaq Biotechnology Index Inclusion: Immuneering's addition to the Nasdaq Biotechnology Index signifies increased recognition within the industry, potentially attracting more investor interest in its future developments.
See More
IMMUNEERING CORP SET TO RELEASE EXPANDED PANCREATIC CANCER COHORT DATA IN EARLY 2026
Immuneering Corp Update: Immuneering Corp is on track for an expanded pancreatic cancer cohort data readout scheduled for the first half of 2026.
Focus on Cancer Research: The company is emphasizing its commitment to advancing research in pancreatic cancer through its innovative approaches.
See More
U.S. Stocks Rise on Venezuela Action; Chevron Shares Up 5.8%
- Market Rally: U.S. equities wrapped the first full trading week of 2026 on a strong note, with both the S&P 500 and Dow Jones Industrial Average reaching new record highs, reflecting investor optimism about economic recovery.
- Energy Stocks Surge: Following U.S. military actions in Venezuela, Chevron shares rose approximately 5.8%, as investors expressed optimism about potential access to the country's oil resources, highlighting the direct impact of geopolitical events on market performance.
- Defense Stocks Rise: Anticipation of a significantly larger Pentagon budget in 2027 led to substantial gains for defense contractors, indicating a strong market focus on defense spending and confidence in future growth prospects.
- Mixed Economic Data: The December jobs report revealed slower-than-expected payroll growth but a declining unemployment rate, easing investor concerns about labor market stress and supporting the narrative that the Fed may hold rates steady in the near term.
See More
U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction
- Jobless Claims Increase: U.S. initial jobless claims rose by 8,000 to 208,000 for the week ending January 3, slightly below market expectations of 210,000, indicating ongoing labor market pressures that could affect economic recovery confidence.
- Productivity Gains: Nonfarm business sector labor productivity increased by 4.9% in Q3, following a revised 4.1% gain in the previous quarter, suggesting progress in efficiency improvements that may support future economic growth.
- Unit Labor Costs Decline: Unit labor costs in the nonfarm business sector fell by 1.9% in Q3, contrary to market expectations of a 1.0% increase, indicating successful cost control by businesses that could bolster profit margins.
- Trade Deficit Shrinks: The U.S. trade deficit narrowed to $29.4 billion in October, the smallest gap since June 2009, significantly lower than the revised $48.1 billion deficit in September, reflecting improved international trade conditions that may contribute to economic stability.
See More
Acuity Inc. Reports 20.2% Revenue Growth in Q1 2026
- Revenue Growth: Acuity Inc. reported a 20.2% year-over-year increase in net sales for Q1 2026, reaching $1.14 billion, aligning with analyst consensus estimates and demonstrating ongoing momentum in its intelligent building solutions business.
- Earnings Beat: The company posted an adjusted EPS of $4.69, surpassing the analyst consensus of $4.59, indicating enhanced profitability that may attract more investor interest.
- Positive Market Reaction: Acuity's strong earnings report led to a rise in its stock price, reflecting market confidence in its future growth potential, particularly against the backdrop of sustained demand in the intelligent building sector.
- Industry Leadership: This performance not only solidifies Acuity's leadership position in the intelligent building solutions market but also positions the company for potential market share expansion and increased competitive advantage in the future.
See More
Immuneering Updates Pancreatic Cancer Trial Data, Survival Rates Show Significant Improvement
- Survival Rate Comparison: In the pancreatic cancer trial, patients receiving the atebimetinib combination therapy had a 12-month survival rate of 64%, significantly higher than the 35% for those on chemotherapy alone, indicating the potential advantages of the new treatment.
- Progression-Free Survival: The median progression-free survival for the atebimetinib group was 8.5 months, compared to 5.5 months for the chemotherapy group, demonstrating the new regimen's effectiveness in delaying disease progression.
- Safety Profile: As of December 15, 2025, the atebimetinib + mGnP regimen exhibited a favorable safety profile, with adverse events at Grade 3 occurring in over 10% of patients, indicating good tolerability of the combination therapy.
- Upcoming Catalysts: Data from an expanded cohort of 50 patients is expected in the first half of 2026, with plans to initiate a pivotal Phase 3 trial in mid-2026, showcasing the company's ongoing commitment and growth potential in pancreatic cancer treatment.
See More
Immuneering Reports Q4 EPS Beat with Strong Cash Position
- Earnings Highlights: Immuneering reported a Q4 GAAP EPS of -$0.18, beating expectations by $0.13, indicating resilience in financial performance despite a challenging market environment.
- Strong Cash Reserves: As of 2025, Immuneering holds $217 million in cash, cash equivalents, and marketable securities, with an anticipated runway extending into 2029, ensuring operational stability for the coming years.
- Clinical Trial Progress: The company reported a positive 12-month overall survival update from the Phase IIa trial of Atebimetinib for pancreatic cancer, demonstrating potential therapeutic value despite a stock price decline due to data volatility.
- Nasdaq Biotechnology Index Inclusion: Immuneering's addition to the Nasdaq Biotechnology Index signifies increased recognition within the industry, potentially attracting more investor interest in its future developments.
See More
IMMUNEERING CORP SET TO RELEASE EXPANDED PANCREATIC CANCER COHORT DATA IN EARLY 2026
Immuneering Corp Update: Immuneering Corp is on track for an expanded pancreatic cancer cohort data readout scheduled for the first half of 2026.
Focus on Cancer Research: The company is emphasizing its commitment to advancing research in pancreatic cancer through its innovative approaches.
See More
U.S. Stocks Rise on Venezuela Action; Chevron Shares Up 5.8%
- Market Rally: U.S. equities wrapped the first full trading week of 2026 on a strong note, with both the S&P 500 and Dow Jones Industrial Average reaching new record highs, reflecting investor optimism about economic recovery.
- Energy Stocks Surge: Following U.S. military actions in Venezuela, Chevron shares rose approximately 5.8%, as investors expressed optimism about potential access to the country's oil resources, highlighting the direct impact of geopolitical events on market performance.
- Defense Stocks Rise: Anticipation of a significantly larger Pentagon budget in 2027 led to substantial gains for defense contractors, indicating a strong market focus on defense spending and confidence in future growth prospects.
- Mixed Economic Data: The December jobs report revealed slower-than-expected payroll growth but a declining unemployment rate, easing investor concerns about labor market stress and supporting the narrative that the Fed may hold rates steady in the near term.
See More
U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction
- Jobless Claims Increase: U.S. initial jobless claims rose by 8,000 to 208,000 for the week ending January 3, slightly below market expectations of 210,000, indicating ongoing labor market pressures that could affect economic recovery confidence.
- Productivity Gains: Nonfarm business sector labor productivity increased by 4.9% in Q3, following a revised 4.1% gain in the previous quarter, suggesting progress in efficiency improvements that may support future economic growth.
- Unit Labor Costs Decline: Unit labor costs in the nonfarm business sector fell by 1.9% in Q3, contrary to market expectations of a 1.0% increase, indicating successful cost control by businesses that could bolster profit margins.
- Trade Deficit Shrinks: The U.S. trade deficit narrowed to $29.4 billion in October, the smallest gap since June 2009, significantly lower than the revised $48.1 billion deficit in September, reflecting improved international trade conditions that may contribute to economic stability.
See More
Acuity Inc. Reports 20.2% Revenue Growth in Q1 2026
- Revenue Growth: Acuity Inc. reported a 20.2% year-over-year increase in net sales for Q1 2026, reaching $1.14 billion, aligning with analyst consensus estimates and demonstrating ongoing momentum in its intelligent building solutions business.
- Earnings Beat: The company posted an adjusted EPS of $4.69, surpassing the analyst consensus of $4.59, indicating enhanced profitability that may attract more investor interest.
- Positive Market Reaction: Acuity's strong earnings report led to a rise in its stock price, reflecting market confidence in its future growth potential, particularly against the backdrop of sustained demand in the intelligent building sector.
- Industry Leadership: This performance not only solidifies Acuity's leadership position in the intelligent building solutions market but also positions the company for potential market share expansion and increased competitive advantage in the future.
See More
Immuneering Updates Pancreatic Cancer Trial Data, Survival Rates Show Significant Improvement
- Survival Rate Comparison: In the pancreatic cancer trial, patients receiving the atebimetinib combination therapy had a 12-month survival rate of 64%, significantly higher than the 35% for those on chemotherapy alone, indicating the potential advantages of the new treatment.
- Progression-Free Survival: The median progression-free survival for the atebimetinib group was 8.5 months, compared to 5.5 months for the chemotherapy group, demonstrating the new regimen's effectiveness in delaying disease progression.
- Safety Profile: As of December 15, 2025, the atebimetinib + mGnP regimen exhibited a favorable safety profile, with adverse events at Grade 3 occurring in over 10% of patients, indicating good tolerability of the combination therapy.
- Upcoming Catalysts: Data from an expanded cohort of 50 patients is expected in the first half of 2026, with plans to initiate a pivotal Phase 3 trial in mid-2026, showcasing the company's ongoing commitment and growth potential in pancreatic cancer treatment.
See More
